Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

New danger? Popular weight loss drugs and diabetes medications may trigger permanent eye damage! New study raises serious ...

Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Administered as a once-weekly subcutaneous injection, Ozempic not only helps control blood glucose levels but also reduces ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...